Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22): early-phase trial registry
All 26 indexed Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) trials have closed enrollment; the archived set skews early-phase.
Corpus placement: #627 of 28,707 conditions by registered trial count.
26 US clinical trials · none currently recruiting · #627 of 28,707 conditions by registered trial count
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22): 26 US clinical trials tracked, none currently recruiting.
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) is the subject of 26 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 3 are in Phase 3-4 (later-stage) and 19 in Phase 1-2 (earlier-stage). The most active sponsor is Fred Hutchinson Cancer Center, running 9 of these trials.
Enrollment posture brief
Registry condition adult-acute-myeloid-leukemia-with-t1616p13q22
OPEN 0 | RECR 0% | LATE 3 | EARLY 19 | RANK #627 | SPON 9
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) has no open enrollment in this registry pull (26 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) is recruiting below its size-band peers.
0 of 26 indexed trials (0%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) research.
Fred Hutchinson Cancer Center accounts for 9 of 26 trials (34.6%). 10 distinct sponsors appear on at least one study for this condition label.
-
Most Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) trials plan to enrol fewer than 100 people.
Median target enrolment is 43 among the 26 trials that report a genuine target (sentinel values excluded). 20 of those (76.9%) plan for fewer than 100 participants.
-
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) research is mostly interventional.
25 interventional and 1 observational studies make up this index (96.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Indexed trials (enrollment closed)
26 total, page 1 of 1
Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant
City of Hope Medical Center
NCT01199562
Total Marrow and Lymphoid Irradiation and Chemotherapy Before DSCT in Treating Patients With High-Risk ALL or AML
City of Hope Medical Center
NCT02094794
Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
NCT00799461
Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia
National Cancer Institute (NCI)
NCT00003190
Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
National Cancer Institute (NCI)
NCT01349972
Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
Fred Hutchinson Cancer Center
NCT00489203
Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
National Cancer Institute (NCI)
NCT00634244
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
University of Chicago
NCT01839916
CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase
National Cancer Institute (NCI)
NCT00084916
Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome
Fred Hutchinson Cancer Center
NCT00445744
GTI-2040 and High-Dose Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia
National Cancer Institute (NCI)
NCT00070551
Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm
University of Washington
NCT01101880
Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant
Fred Hutchinson Cancer Center
NCT01083706
Bendamustine and Idarubicin in Treating Older Patients With Previously Untreated AML or MDS
Fred Hutchinson Cancer Center
NCT01141725
Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation
Fred Hutchinson Cancer Center
NCT00052520
Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer
National Cancer Institute (NCI)
NCT00012376
Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies
Sumithira Vasu
NCT02122081
Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia
Fred Hutchinson Cancer Center
NCT00322101
A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies
Fred Hutchinson Cancer Center
NCT00343798
Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
NCT00408681
Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
University of Wisconsin, Madison
NCT01707004
Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies
Nohla Therapeutics
NCT01175785
PXD101 in Treating Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
NCT00357032
Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Sumithira Vasu
NCT02316964
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer
Fred Hutchinson Cancer Center
NCT00112593
Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia
Case Comprehensive Cancer Center
NCT01127009
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 11 |
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) page
26 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Fred Hutchinson Cancer Center sponsors the most Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) trials on record, review their full trial history before evaluating a specific study. See Fred Hutchinson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) condition card totals 26 registered trials; most-linked intervention laboratory biomarker analysis; top US site state Washington. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.